Name | Number of supported studies | Average coverage | |
---|---|---|---|
hepatocyte | 3 studies | 38% ± 13% |
Insufficient scRNA-seq data for expression of AKR1C4 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 7961.20 | 226 / 226 | 97% | 205.74 | 395 / 406 |
lung | 85% | 6.12 | 493 / 578 | 24% | 1.88 | 281 / 1155 |
kidney | 90% | 6.79 | 80 / 89 | 12% | 0.40 | 110 / 901 |
stomach | 64% | 5.08 | 229 / 359 | 38% | 1.89 | 109 / 286 |
pancreas | 53% | 3.19 | 173 / 328 | 40% | 2.33 | 72 / 178 |
intestine | 47% | 3.63 | 458 / 966 | 35% | 2.37 | 183 / 527 |
esophagus | 36% | 1.35 | 522 / 1445 | 36% | 1.54 | 65 / 183 |
adipose | 64% | 4.23 | 765 / 1204 | 0% | 0 | 0 / 0 |
breast | 61% | 3.36 | 280 / 459 | 1% | 0.02 | 11 / 1118 |
bladder | 43% | 1.43 | 9 / 21 | 14% | 0.69 | 71 / 504 |
spleen | 53% | 9.05 | 127 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 50% | 26.34 | 462 / 929 | 0% | 0 | 0 / 0 |
adrenal gland | 40% | 1.39 | 104 / 258 | 8% | 0.25 | 18 / 230 |
thymus | 38% | 1.36 | 248 / 653 | 0% | 0 | 0 / 605 |
skin | 33% | 1.33 | 589 / 1809 | 0% | 0.01 | 2 / 472 |
muscle | 32% | 1.15 | 253 / 803 | 0% | 0 | 0 / 0 |
heart | 31% | 1.26 | 266 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 30% | 1.15 | 407 / 1335 | 0% | 0 | 0 / 0 |
uterus | 23% | 0.93 | 39 / 170 | 6% | 0.24 | 26 / 459 |
ovary | 21% | 0.54 | 37 / 180 | 4% | 0.20 | 17 / 430 |
prostate | 24% | 0.72 | 58 / 245 | 1% | 0.01 | 4 / 502 |
brain | 17% | 0.54 | 452 / 2642 | 1% | 0.01 | 5 / 705 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0044597 | Biological process | daunorubicin metabolic process |
GO_0008209 | Biological process | androgen metabolic process |
GO_0044598 | Biological process | doxorubicin metabolic process |
GO_0071395 | Biological process | cellular response to jasmonic acid stimulus |
GO_0042448 | Biological process | progesterone metabolic process |
GO_0015721 | Biological process | bile acid and bile salt transport |
GO_0001523 | Biological process | retinoid metabolic process |
GO_0006693 | Biological process | prostaglandin metabolic process |
GO_0006699 | Biological process | bile acid biosynthetic process |
GO_0008202 | Biological process | steroid metabolic process |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0015125 | Molecular function | bile acid transmembrane transporter activity |
GO_0047024 | Molecular function | 5alpha-androstane-3beta,17beta-diol dehydrogenase activity |
GO_0047086 | Molecular function | ketosteroid monooxygenase activity |
GO_0004032 | Molecular function | aldose reductase (NADPH) activity |
GO_0047044 | Molecular function | androstan-3-alpha,17-beta-diol dehydrogenase activity |
GO_0016655 | Molecular function | oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor |
GO_0047023 | Molecular function | androsterone dehydrogenase activity |
GO_0009055 | Molecular function | electron transfer activity |
GO_0004033 | Molecular function | aldo-keto reductase (NADPH) activity |
GO_0047035 | Molecular function | testosterone dehydrogenase (NAD+) activity |
GO_0001758 | Molecular function | retinal dehydrogenase activity |
GO_0032052 | Molecular function | bile acid binding |
GO_0047045 | Molecular function | testosterone 17-beta-dehydrogenase (NADP+) activity |
GO_0004303 | Molecular function | estradiol 17-beta-dehydrogenase [NAD(P)+] activity |
GO_0035410 | Molecular function | dihydrotestosterone 17-beta-dehydrogenase activity |
GO_0047743 | Molecular function | chlordecone reductase activity |
Gene name | AKR1C4 |
Protein name | Aldo-keto reductase family 1 member C4 (EC 1.1.1.-) (EC 1.1.1.209) (EC 1.1.1.210) (EC 1.1.1.51) (EC 1.1.1.53) (EC 1.1.1.62) (3-alpha-hydroxysteroid dehydrogenase type I) (3-alpha-HSD1) (EC 1.1.1.357) (3alpha-hydroxysteroid 3-dehydrogenase) (Chlordecone reductase) (CDR) (EC 1.1.1.225) (Dihydrodiol dehydrogenase 4) (DD-4) (DD4) (HAKRA) |
Synonyms | CHDR |
Description | FUNCTION: Cytosolic aldo-keto reductase that catalyzes the NADH and NADPH-dependent reduction of ketosteroids to hydroxysteroids. Liver specific enzyme that acts as an NAD(P)(H)-dependent 3-, 17- and 20-ketosteroid reductase on the steroid nucleus and side chain . Displays the ability to catalyze both oxidation and reduction in vitro, but most probably acts as a reductase in vivo since the oxidase activity measured in vitro is inhibited by physiological concentration of NADPH . Acts preferentially as a 3-alpha-hydroxysteroid dehydrogenase (HSD) with a subsidiary 3-beta-HSD activity . Catalyzes efficiently the transformation of the potent androgen 5-alpha-dihydrotestosterone (5alpha-DHT or 17beta-hydroxy-5alpha-androstan-3-one) into the less active form, 5-alpha-androstan-3-alpha,17-beta-diol (3-alpha-diol) . Catalyzes the reduction of estrone into 17beta-estradiol but with low efficiency . Metabolizes a broad spectrum of natural and synthetic therapeutic steroid and plays an important role in metabolism of androgens, estrogens, progestereone and conjugated steroids . Catalyzes the biotransformation of the pesticide chlordecone (kepone) to its corresponding alcohol leading to increased biliary excretion of the pesticide and concomitant reduction of its neurotoxicity since bile is the major excretory route . . |
Accessions | P17516 ENST00000380448.5 ENST00000263126.3 |